Company intelligence / Profile preview
Pharmicell Co., Ltd.
Gangnam-gu, Seoul-si, South Koreapharmicell.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Pharmicell developed the world's first stem cell therapy (Hearticellgram-AMI) approved in 2011. They have multiple programs in clinical trials, including treatments for liver cirrhosis and erectile dysfunction.
- Therapeutic areas
- GastroenterologyOncologyCardiovascularMen's Health
- Modalities
- Stem Cell TherapyDendritic Cell TherapyPharmaceutical Intermediates
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Thermo FisherMerck
Beyond the preview
Go deeper on Pharmicell Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmicell Co., Ltd..